Revised Procedures for CDR and pCODR For all drug applications filed for review through either the Common Drug Review (CDR) or pan-Canadian Oncology Drug Review (pCODR) process on or after April 1, 2016, CADTH will no longer accept confidential submitted prices. The submitted price will be disclosed in all applicable CDR ...
pCPA February Update – Federal Drug Plans officially join the pCPA and the full Office team is now in place
In a recent update released to their website, the pan-Canadian Pharmaceutical Alliance (pCPA) announced 2 significant developments: The Federal Drug Plans are now participating in the pCPA; and The Office of the pCPA (the Office) is now fully staffed. On January 19, 2016 the Government of Canada issued a News Release ...
Ontario has released the February 2016 Summary of Changes document, which includes the addition of Hospira’s Inflectra at a price of $525.00. Please see page 4 of the Summary of Changes document for more information regarding the clinical criteria and listing status of Inflectra.
The Alberta Price Confirmation (APC) is issued prior to an Alberta Drug Benefit List (ADBL) publication. The APC is a requirement for listing on the ADBL. The APC Tentative Issue Dates are subject to change. ADBL Effective Date APC Tentative Issue Date March 1, 2016 February 2, 2016 April 1, 2016 February 18, ...
Modifications to the Procedure for Filing a Drug Submission Application for Generic Drugs with INESSS
Since Québec is now participating in the pan-Canadian Pharmaceutical Alliance (pCPA), INESSS recently communicated that information sharing has now become necessary to ensure greater efficiency when conducting drug reviews. As of February 15, 2016, a supplementary document, supporting authorization of information sharing with pCPA, must accompany any drug submission application pertaining ...
The objective of this preliminary report is to summarize PDCI’s assessment of the national pharmacare cost estimate study (Morgan et al) and identify some alternative mechanisms by which drug coverage in Canada can fulfill the spirit of the Canada Health Act plus the objectives of equity and sustainability. The final ...
On November 24, 2015, Québec’s Minister of Health and Social Services, Gaétan Barrette introduced the following bill to Quebec’s National Assembly: Bill 81: An Act to reduce the cost of certain medications covered by the basic prescription drug insurance plan by allowing calls for tender. Bill 81 would amend the Act Respecting ...
Ontario has released a summary, titled Minister’s Roundtable on Pan-Canadian Pharmacare, based on a roundtable discussion on pharmacare hosted by the Honourable Dr. Eric Hoskins, Ontario’s Minister of Health and Long-Term Care, on June 8, 2015. This summary, prepared by Health Quality Ontario, provides an overview of the discussion which ...
PDCI has developed considerable expertise assisting manufacturers with product listing agreements(PLAs) through the pan-Canadian Pharmaceutical Alliance (pCPA), with individual provinces (including Quebec) and with private payers. With the formalization of the pCPA process and private payers moving aggressively into the PLA environment (see PDCIs white paper), PDCI is growing ...
INESSS is offering an opportunity for in-person meetings to manufacturers who have filed a submission by the deadline for drugs to be listed on the June 2016 “Liste des médicaments”. These meetings will be held between December 7 and December 18, 2015, inclusive. Meetings will cover the following: Discussion on clinical studies Discussion ...